Objectives: Aim of the study was to assess in-hospital survival rate and the degree of myocardial recovery after MCS treatment (IABP or IMPELLA) at discharge and at 6 months in patients with AMI-CS and planned early percutaneous revascularization.
| MATERIALS AND METHODS

| Study design
We performed a retrospective study of all patients (n = anonymized prior to analysis. In particular, we compared patients receiving intra-aortic balloon pump (IABP) with patients treated with Impella 2.5 or Impella CP (ABIOMED, Danvers, MA) LV pump. Inclusion criteria were ACS complicated by cardiogenic shock with planned early revascularization by percutaneous coronary intervention (PCI) and age >17 years old. Exclusion criteria were no intrinsic heart activity, need for CPR, mechanical causes of cardiogenic shock, profound shock requiring venoarterial extracorporeal membrane oxygenation (VA ECMO), onset of shock longer than 12 h, severe peripheral artery disease precluding IABP/Impella insertion, aortic regurgitation greater than moderate, age greater than 90 years, shock of other cause, and other severe concomitant disease with life expectancy less than 6 months.
In-hospital records were evaluated for data regarding baseline patient characteristics (including parameters of severity of the shock, coronary artery disease), procedural characteristics, and outcomes data (complications of the devices, acute organ injury, hospital survival). Moreover, short-term and long-term outcome data were evaluated ( Figure 1 ).
| End points
The primary endpoints of our study were in-hospital survival and the degree of myocardial recovery after MCS treatment measured as the improvement of left ventricular ejection fraction (LVEF%) at discharge and at 6 months. 
| Revascularization
All patients underwent primary PCI: it was performed using standard equipment and techniques with the use of drug-eluting stents as well as dual antiplatelet therapy at the discretion of the treating cardiologist.
Multi-vessel coronary artery disease was defined as the presence of a coronary stenosis (stenosis degree >50%) in >1 main coronary artery. In multi-vessel disease, the mode of revascularization (immediate or staged PCI of the non-culprit lesions) was left to the discretion of the operator.
| Definitions
| Clinical definitions
Chronic renal failure was defined by GFR < 60 mL/min/1.73 m 2 for ≥3 months. New York Heart Association (NYHA) classification is used to grade the severity of functional limitations in a patient with heart failure. 6 Canadian Cardiovascular Society grading is a classification system used to grade the severity of angina pectoris.
| Assessment of infart-size and myocardial recovery
Infart size was measured as the degree of LVEF reduction after ACS and the troponin and CPK peak.
Myocardial recovery after MCS treatment was measured as the degree of LVEF improvement at discharge and at 6 months.
| Inotropic score
The inotropic score was calculated before procedure and over the first Bleeding in hospital were defined by GUSTO 9 bleeding. According to institutional policy it was applied a liberal strategy for red cell transfusion with a threshold of hematocrit 30%. 3 | RESULTS
| Statistical analysis
| Baseline characteristics
Sixty-four patients treated for AMI-CS at our center were included in this study: of these, 36 (56%) received IABP support and 28 had treatment with Impella (44%). Patients characteristics are reported in Table 1 .
There were no statistically significant differences between Impella group and IABP group regarding the prevalence of STEMI, NSTEMI, anterior wall myocardial, and involvement of left anterior descending artery. More severe acute cardiac function impairment was recorded in the Impella group compared to IABP patients (LVEF 21 ± 7 vs 26 ± 8%, P = 0.02).
All clinical and laboratory variables are shown in Table 1 .
Patients treated with Impella were overall more acutely critically ill compared to IABP patients as shown by the following considerations.
First, they presented a higher need of catecholamines at procedure (93% Impella vs 57% IABP, P = 0.002) and a higher inotropic score before procedure [8 (5-15) vs 4.5 (0-9), P = 0.02]. Second, acute organ injury parameters, including the presence of acute renal failure (29% vs 2.9%, P = 0.008), oliguria (54% vs 8.3%, P < 0.0001), altered mental status before procedure (71% vs 44%, P = 0.03), cold and clammy skin and extremities (82% vs 58%, P = 0.058), were more altered in Impella patients, which also presented higher creatinine (1.45 ± 0.71 mg/dL vs 1.15 ± 0.35 mg/dL, P = 0.029) and lower creatinine clearance at procedure (58.5 ± 23.2 mL/h vs 72.8 ± 31.1 mL/h, P = 0.047).
Impella patients had a earlier implant of the device compared to IABP patients, with a median of 60 min (55-100) versus 220
(150-300) min from admission respectively (P < 0.0001); 43% Impella versus 58% IABP were implanted before PCI (P = 0.3) ( Table 2 ).
All patients underwent primary PCI: among patients with bivasal and trivasal coronary artery disease, 63% of Impella underwent PCI only of the culprit lesion versus 80% of IABP patients (P = 0.30).
| In-hospital and mid-term outcomes
There were no significant differences between Impella versus IABP patients as for 30-day survival (79% vs 94%, P = 0.1) ( Table 2 ).
This was further confirmed at 6-month survival (75% Impella vs 92% IABP, P = 0.09).
Patients who implanted Impella before PCI had a lower troponin No statistically significant differences were observed in the rate of peripheral ischemic complications, sepsis, life-threatening, severe bleeding in hospital, moderate or mild bleeding in hospital. Hemolysis was more frequent in the Impella group (32% vs 0% IABP, P < 0.0001) ( Table 2) . (Table 2) . LVEF increase from admission to 6 months is statistically significant in both groups (P ≤ 0.0001); analysis of variance of LVEF showed as larger myocardial recovery in patients who received Impella (absolute delta LVEF increase 20% vs 10%, P = 0.0057) (Figure 2 ).
There were no significant differences between the two groups on the implantation rate of ICD at 6 months (19% Impella vs 12% IABP, P = 0.5).
| DISCUSSION
Our study shows no differences in in-hospital, 30 days and 6 months survival between AMICS patients treated with Impella compared to IABP. This is remarkable, as patients treated with Impella were more critically ill at hospital admission in our study population as demonstrated by 30-days mortality predictors 10 : prior MI, altered mental status before procedure, oliguria, and low LVEF at admission.
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Interestingly, patients treated with Impella experience a greater myocardial recovery at 6 months compared to IABP patients and a reduced infarct-size if Impella is started before PCI.
Since the implementation of guidelines recommended early revascularization after the results of the SHOCK trial 12,13 mortality in AMI patients complicated by CS has steadily decreased to <50%; however, it is still extremely high and cardiogenic shock remains the leading cause of death in patients hospitalized with AMI. IABP-SHOCK II trial showed no survival benefit with IABP support by comparison with control at 30 days, 6 and 12 months, indeed mortality was still slightly higher than 50% at 1 year follow-up. 14 In the IMPRESS trial, Impella CP support was not associated with lower 30-day nor 6-month mortality when compared with IABP support and there were no differences in the degree of myocardial recovery as measured by LVEF after 2.5 months. 15 It is to be noted, however, that the IMPRESS trial was a pilot trial not sufficiently powered to show superiority or inferiority of Impella CP over IABP.
Moreover, cardiac arrest rate was 92%, 15 compared to 39% in our study and this may partially explain the different results observed.
Based on our data, suggesting that patients who undergo Impella implantation before PCI experience reduced infarct size, we might also speculate that the high rate of post-PCI Impella implantation in the IMPRESS trial might have played a role in the outcomes observed.
One of the most important findings of our study is the low inhospital mortality (12.5%). Our strategy was to adopt a rapid triage and treatment algorithms for CS with a similar approach currently employed for STEMI, whereby early diagnosis, emergent network activation, short DTB coronary reperfusion times and short "door to support" (DTS) are routinely implemented. 16 According to this strategy of early MCS, in our study DTS time has been very short; indeed, it was shorter for patients who received Impella because they had more compromised conditions.
Moreover, the low rate of MCS-related complications demonstrates the feasibility and the safety of an early strategy of MCS to counterbalance the negative consequences on acidosis and peripheral perfusion which can be observed with high doses of inotropes. The targets of an early strategy of MCS are to unload LV reducing wall stress and reperfusion injury after AMI, to avoid high dose of inotropes (starting MCS before inotropic score is >20) and to provide a blood flow that allows the operator to perform a safe revascularization.
Several recent reports support that concept of a DTS time and have observed improved survival with early initiation of MCS before percutaneous coronary revascularization or before the initiation of inotropes and vasopressors in the setting of AMI-CS. 17 As already mentioned, our study further confirms that initiation of we acknowledge that patients in the Impella group were sicker and in more profound cardiogenic shock, though yielding survival rates.
| Limitations
Our study has some limitations. Namely, the retrospective nonrandomized nature of the registry design as choice of the device, timing of MCS, decision of the extent of revascularization, and all other adjunctive therapies were left to the operating physicians team and are therefore subject to treatment biases. Since our data are the result of a single center registry, another limitation of this study is the small number of patients, which did not allow a meaningful evaluation of potential mortality differences and myocardial recovery after CS. We also acknowledge that the two populations under study were different and that we did not perform a propensity-matched analysis.
Furthermore, the study was not powered to demonstrate differences in survival between the two groups. The analysis might have been confounded, in addiction, by the fact that the outcomes in Impella patients were analyzed in a small number of patients, as some patients died and some underwent LVAD implantation: as a matter of fact, the study aimed at evaluating the amount of myocardial recovery in those patients who had recoverable myocardium. LVAD implantation is indeed required in those who have extensive myocardial necrosis and massive loss of contractile function despite reperfusion. The preliminary evidence from this study is, in this sense, precious to encourage and promote further larger studies.
| CONCLUSIONS
Cardiogenic shock following acute myocardial infarction is a medical emergency necessitating a rapid triage and dedicated treatment algorithms: early diagnosis, emergent network activation, and short FIGURE 2 Repeated measures ANOVA for left ventricular ejection fraction (LVEF) at procedure, at discharge and at 6 months after cardiogenic shock. There is an increase of LVEF from admission to 6 months regardless which device is used (P ≤ 0.0001); myocardial recovery is better in patients who received Impella (P = 0.0057) PIERI ET AL.
| 723 door-to-balloon time with coronary reperfusion time have substantially reduced in-hospital mortality. However, in patients with cardiogenic shock, implementation of a "door to support" strategy can yield excellent survival rates, regardless of the device used. The Impella system has a powerful effect in sicker patients and promotes reduction of myocardial damage, especially if implanted before PCI, which turns into improved outcomes at 6 months. These results give a new perspective to the field of mechanical circulatory support in patients suffering from acute coronary syndrome and might further expend the application of the Impella technology to those who have a large amount of myocardium at risk, though not in overt shock.
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